NCCN Hosts 2011 Congress Series: Gastrointestinal Cancers™
Carrie Capili, Communications Specialist, Editor
On Monday, October 10, 2011, the National Comprehensive Cancer Network® (NCCN®) hosted the NCCN 2011 Congress Series: Gastrointestinal Cancers™ in Chicago, IL. This full-day educational program was attended by more than 225 people, including expert clinicians, nurses, pharmacists, and other health care professionals interested in understanding the most up-to-date treatment recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for gastrointestinal cancers. As research continues in these areas and new information emerges, it is critical that clinicians are kept current and informed.
Moderated by NCCN Board of Directors member and Colon/Rectal/Anal Cancers Panel Chair Al B. Benson III, MD, FACP, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the Congress presented an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for colon, gastric/esophageal, hepatocellular, pancreatic, and rectal cancers, collectively the gastrointestinal cancers, and discussion regarding how to implement the NCCN Guidelines recommendations into the practices of oncologists and clinical professionals.
Speakers at the Congress included esteemed faculty experts from the following NCCN Member Institutions: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Duke Cancer Institute, The University of Texas MD Anderson Cancer Center, Fox Chase Cancer Center, Huntsman Cancer Institute at the University of Utah, UCSF Helen Diller Family Comprehensive Cancer Center, and Memorial Sloan-Kettering Cancer Center.
The Congress opened with several sessions on colorectal cancer, including Treatment of Localized Rectal Cancer, Treatment of Localized Colon Cancer, Adjuvant Treatment for Colorectal Cancer, Treatment of Metastatic Colorectal Cancer, and NCCN Outcomes Database: Colorectal Cancer. Sessions on the screening of high-risk patients, treatment and management of hepatocellular and pancreatic cancers were also presented. The Congress closed with sessions on Treatment of Local Disease: The Role of Neoadjuvant and Adjuvant Therapy and Management of Metastatic Disease for gastric/esophageal cancer.
Overall, the Congress provided attendees with a comprehensive educational experience related to the NCCN Guidelines for gastrointestinal cancers as they evolve and continue to be updated with the most current research and new therapies in oncology practice today.